Src Family Kinases Promote Silencing of ATR-Chk1 Signaling in Termination of DNA Damage Checkpoint-Reference-Cited by-同舟云学术

Src Family Kinases Promote Silencing of ATR-Chk1 Signaling in Termination of DNA Damage Checkpoint

Published:2014-05 Issue:18 Volume:289 Page:12313-12329
ISSN:0021-9258
Container-title:Journal of Biological Chemistry
language:en
Short-container-title:Journal of Biological Chemistry

Author:

Fukumoto Yasunori,Morii Mariko,Miura Takahito,Kubota Sho,Ishibashi Kenichi,Honda Takuya,Okamoto Aya,Yamaguchi Noritaka,Iwama Atsushi,Nakayama Yuji,Yamaguchi Naoto

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry

Reference96 articles.

1. DNA damage checkpoints: from initiation to recovery or adaptation;Bartek;Curr. Opin. Cell Biol,2007

2. Turning off the G2 DNA damage checkpoint;Calonge;DNA Repair,2008

3. DNA damage checkpoint inactivation: adaptation and recovery;Clémenson;DNA Repair,2009

4. ATR: an essential regulator of genome integrity;Cimprich;Nat. Rev. Mol. Cell Biol,2008

5. Recognition, signaling, and repair of DNA double-strand breaks produced by ionizing radiation in mammalian cells: the molecular choreography;Thompson;Mutat. Res,2012

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DNA damage‐induced allosteric activation of protein phosphatase PP1:NIPP1 through Src kinase‐induced circularization of NIPP1;The FEBS Journal;2024-02

2. Unravelling the molecular basis of PARP inhibitor resistance in prostate cancer with homologous recombination repair deficiency;International Review of Cell and Molecular Biology;2024

3. The C-terminal tail of Rad17, iVERGE, binds the 9‒1‒1 complex independently of AAA+ ATPase domains to provide another clamp–loader interface;DNA Repair;2023-10

4. The Androgen Receptor and Its Crosstalk With the Src Kinase During Castrate-Resistant Prostate Cancer Progression;Frontiers in Oncology;2022-06-27

5. Inhibiting Src-mediated PARP1 tyrosine phosphorylation confers synthetic lethality to PARP1 inhibition in HCC;Cancer Letters;2022-02